Refine
Year of publication
Document Type
- Preprint (611)
- Article (434)
- Conference Proceeding (1)
- Report (1)
- Working Paper (1)
Has Fulltext
- yes (1048)
Is part of the Bibliography
- no (1048)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron scattering (experiments) (11)
- Hadron-Hadron Scattering (8)
- Heavy-ion collision (5)
- Collective Flow (4)
- Quark-Gluon Plasma (4)
- Jets (3)
- Jets and Jet Substructure (3)
- (surface) partial differential equations (2)
- 3D spatio-temporal resolved mathematical models (2)
- Atmospheric chemistry (2)
- COVID-19 (2)
- Epilepsy (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Finite Volumes (2)
- Germany (2)
- Heavy Quark Production (2)
- Immunotherapy (2)
- LHC (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Non-small cell lung cancer (2)
- Oncology (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Quarkonium (2)
- acute myeloid leukemia (2)
- computational virology (2)
- immunotherapy (2)
- massively parallel multigrid solvers (2)
- realistic geometries (2)
- viral dynamics (2)
- within-host viral modelling (2)
- 140Ce (1)
- 900 GeV (1)
- ACURATE neo (1)
- AIS (1)
- ALICE (1)
- ALICE detector (1)
- APRI (1)
- ASCT (1)
- Accelerators & Beams (1)
- Acute myeloid leukemia (1)
- Adherens junctions (1)
- Aneurysmal subarachnoid hemorrhage (1)
- Anti-nuclei (1)
- Antibody therapy (1)
- Artificial Intelligence (1)
- Atomic and Molecular Physics (1)
- Atomic, Molecular & Optical (1)
- BCOR (1)
- BCORL1 (1)
- BI1361849 (1)
- Bamlanivimab (1)
- Biodiversity Data (1)
- Biogeochemistry (1)
- Biomarkers (1)
- Biomonitoring (1)
- Bladder cancer (1)
- Blood-brain barrier (1)
- Bloodstream infection (1)
- Bloodstream infections (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Brain tumor (1)
- Burkholderia arboris (1)
- CD36 (1)
- CHIP (1)
- CHRNA10 (1)
- CHRNA7 (1)
- CHRNA9 (1)
- CTLA-4 (1)
- CV9202 (1)
- CVID (1)
- Cancer (1)
- Cancer genomics (1)
- Casirivimab (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charged-particle multiplicity (1)
- Checkpoint inhibitor (1)
- Clinical Trials and Observations (1)
- Clinical trial (1)
- Cluster (1)
- Cohort studies (1)
- Collective Flow, (1)
- Conservation (1)
- Correlative electron and light microscopy (1)
- DBS (1)
- DSS /AOM (1)
- Diagnostic markers (1)
- Digitization (1)
- Electromagnetic transitions (1)
- Electron tomography (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Entomology (1)
- Epidemiology (1)
- European Society for Immunodeficiencies (ESID) (1)
- Everolimus resistance (1)
- Evidence-based guidelines (1)
- Extended Glasgow outcome scale (eGOS) (1)
- Extended donor criteria (1)
- FDG-PET/CT (1)
- FIB-4 (1)
- Fibre/foam sandwich radiator (1)
- Freshwater ecology (1)
- GdIr2Si2 (1)
- German PID-NET registry (1)
- Glioma (1)
- Graft function (1)
- Graft survival (1)
- Gram negative bacteria (1)
- HBV (1)
- HDAC-inhibition (1)
- HNSCC (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hard Scattering (1)
- Head neck cancer (1)
- Heavy Ion Experiment (1)
- Hematology (1)
- Hematopoietic stem cell transplantation (1)
- Herbaria (1)
- Hypofractionated radiotherapy (1)
- ICU (1)
- IL -17 (1)
- IL -23 (1)
- IL 23p19 knockout mouse (1)
- ISS (1)
- IgG substitution therapy (1)
- Imdevimab (1)
- Immunomonitoring (1)
- Incidence (1)
- Induction therapy (1)
- Intensive care units (1)
- Invariant Mass Distribution (1)
- Invasive species (1)
- Ionisation energy loss (1)
- Isoflurane (1)
- Jet Physics (1)
- Jet Substructure (1)
- Lesion (1)
- Liver transplantation (1)
- Locally advanced (1)
- Long term output (1)
- Lymphocytes (1)
- Lymphoid tissues (1)
- MACS (1)
- MRI (1)
- Magnetic resonance imaging (MRI) (1)
- Marginal grafts (1)
- Material budget (1)
- Mechanisms of disease (1)
- Minimum Bias (1)
- Models & methods for nuclear reactions (1)
- Molecular diagnostic testing (1)
- Molecular matched therapy (1)
- Molecular medicine (1)
- Molecular profiling (1)
- Monte Carlo (1)
- Mott transition (1)
- Multi-Parton Interactions (1)
- Multi-wire proportional drift chamber (1)
- Multiple parton interactions (1)
- Multivariate analysis (1)
- Myeloid Neoplasia (1)
- NMR spectroscopy (1)
- NSCLC (1)
- Neural network (1)
- Neutron physics (1)
- Neutropenia (1)
- Nivolumab (1)
- Nuclear reactions (1)
- Organ rinse (1)
- Organ shortage (1)
- Osteoporosis (1)
- P2X7 receptor (1)
- PD-1 (1)
- PD-1 inhibitor (1)
- PDEs (1)
- PID prevalence (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pb–Pb collisions (1)
- Phylogenomics (1)
- Pneumonia (1)
- Poecilia mexicana (1)
- Polarization (1)
- Population genetics (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Psoriasis vulgaris (1)
- QCD (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- RNA (1)
- RNA decay (1)
- Radiation detectors (1)
- Radiative capture (1)
- Radical cystectomy (1)
- Radiotherapy (1)
- Rapidity Range (1)
- Registries (1)
- Relativistic heavy-ion collisions (1)
- Renal cell carcinoma (1)
- Research Infrastructure (1)
- Resolution Parameter (1)
- Resonance reactions (1)
- SMAD (1)
- Semantics (1)
- Sexual selection (1)
- Status epilepticus (1)
- Stenotrophomonas maltophilia (1)
- Stentoplasty (1)
- Systematic Uncertainty (1)
- T cell/histiocyte rich large B cell lymphoma (1)
- TAVR (1)
- TGFβ (1)
- TR (1)
- Tacrolimus (1)
- Targeted therapy (1)
- Taxonomy (1)
- Thermodynamics (1)
- Thoracic trauma (1)
- Thrombotic microangiopathy (1)
- Thrombotic thrombocytopenic purpura (1)
- Time Projection Chamber (1)
- TmRh2Si2 (1)
- Tracking (1)
- Transition radiation detector (1)
- Transitional cell carcinoma (1)
- Transverse momentum (1)
- Treatment (1)
- Trigger (1)
- Tumor growth (1)
- Urothelial cancer (1)
- VIM (1)
- Vector Boson Production (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Viral load (1)
- X-ray crystallography (1)
- X-ray irradiation (1)
- Xenon-based gas mixture (1)
- acoustic radiation force impulse imaging (1)
- adaptation (1)
- advanced melanoma (1)
- adversity (1)
- age (1)
- allostasis (1)
- anti-epileptic drug (1)
- aortic stenosis (1)
- autologous stem cell transplantation (1)
- biomarker (1)
- blood cell mutations (1)
- brain metastases (1)
- brain metastasis (1)
- brain shift (1)
- burkholderia (1)
- burkholderia cepacia complex infections (1)
- calcium dynamics (1)
- calcium-independent phospholipase A2β (1)
- capture (1)
- cdk2/cyclin A (1)
- cerebral pseudoprogression (1)
- cerium (1)
- chemoconvulsant (1)
- chemotherapy (1)
- chronic colitis (1)
- clonal dominance (1)
- clonal haematopoiesis (1)
- clonal hematopoiesis (1)
- clonal transfer (1)
- colon cancer (1)
- community assembly (1)
- complete response (1)
- complex systems (1)
- coping (1)
- correlated electrons (1)
- cross-section (1)
- cytarabine dose (1)
- dE/dx (1)
- detailed modeling (1)
- detector (1)
- diffuse large B cell lymphoma (1)
- discontinuation (1)
- discontinuous dose dependency (1)
- disease outbreaks (1)
- disease progression (1)
- disorder (1)
- distributed computation (1)
- dynamic system (1)
- ectosomes (1)
- elderly (1)
- electrical stimulation (1)
- electrophoresis (1)
- epileptogenesis (1)
- essential tremor (1)
- everolimus (1)
- exosomes (1)
- experimental results (1)
- extracellular vesicles (1)
- familial amyloid nephropathy with urticaria and deafness (1)
- female choice (1)
- fibrotest (1)
- flux growth (1)
- gel (1)
- gene expression profiling (1)
- gene signature (1)
- generalized additive model (1)
- genome (1)
- glioblastoma (1)
- guidelines (1)
- head and neck squamous cell carcinoma (1)
- healthcare systems (1)
- heart failure (1)
- heavy ion experiments (1)
- hematopoietic stem cells (1)
- hematopoietic stress (1)
- hepatitis C virus (1)
- hepatitis C virus (HCV) (1)
- hippocampal sclerosis (1)
- homeostasis (1)
- host response (1)
- hybrid (1)
- hypoxia (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitors (1)
- immune checkpoint inhibitors (ICI) (1)
- immune modulation (1)
- immune related adverse events (irAE) (1)
- infections (1)
- inflammasome (1)
- inflammation (1)
- information storage (1)
- inpatient hospital admissions (1)
- interleukin-1β (1)
- leukemia (1)
- liver metastasis (1)
- local information dynamics (1)
- lockdown (1)
- loss-of-function (1)
- low-dose radiation therapy (1)
- lung cancer (1)
- mRNA active cancer immunotherapy (1)
- magnetism (1)
- mathematical models of viral RNA cycle (1)
- medical device (1)
- medical informatics initiative (1)
- mental health (1)
- metastatic renal cell carcinoma (1)
- microbial colonization (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- mouthwash (1)
- mouthwash solution (1)
- n_TOF (1)
- neoadjuvant immunochemotherapy (1)
- neural dynamics (1)
- neurological complication (1)
- neurological side effects (1)
- neuron (1)
- neutron (1)
- nodular lymphocyte predominant Hodgkin lymphoma (1)
- non-independent mate choice (1)
- non-invasive fibrosis assessment (1)
- noncoding RNA (1)
- ntracellular signaling (1)
- nucleosynthesis (1)
- organic conductor (1)
- outbreak (1)
- p+p collisions (1)
- p47phox (1)
- pandemic (1)
- parallel (1)
- parameter estimation (1)
- patterns of progression (1)
- pembrolizumab (1)
- perioperative ischemia (1)
- phase IV (1)
- point shear wave elastography (1)
- postoperative radiochemotherapy (1)
- postoperative radiotherapy (1)
- predator recognition (1)
- predictive coding (1)
- pressure (1)
- primary immunodeficiency (PID) (1)
- propensity score matching (1)
- pulsed-field (1)
- quark gluon plasma (1)
- registry for primary immunodeficiency (1)
- reproducibility (1)
- rigor (1)
- risk stratification (1)
- s-process (1)
- second-line (1)
- second-line immunotherapy (1)
- soil bacteria communities (1)
- somatic mutations (1)
- spatio-temporal analysis (1)
- standardization (1)
- status epilepticus (1)
- stereotactic radiosurgery (1)
- stress (1)
- survival (1)
- targeted therapy (1)
- temporal lobe epilepsy (1)
- transcatheter aortic valve replacement (1)
- transfemoral (1)
- transient elastography (1)
- treatment resistance (1)
- tumor microenvironment (1)
- university hospitals (1)
- uveal melanoma (1)
- variable selection (1)
- ventralis intermedius nucleus (1)
- visual system (1)
- voltage sensitive dye imaging (1)
Institute
- Physik (955)
- Frankfurt Institute for Advanced Studies (FIAS) (852)
- Informatik (822)
- Medizin (66)
- Geowissenschaften (9)
- Biowissenschaften (5)
- ELEMENTS (3)
- Informatik und Mathematik (3)
- Institut für Ökologie, Evolution und Diversität (3)
- Biochemie und Chemie (2)
Aims: Somatic mutations in haematopoietic stem cells can lead to the clonal expansion of mutated blood cells, known as clonal haematopoiesis (CH). Mutations in the most prevalent driver genes DNMT3A and TET2 with a variant allele frequency (VAF) ≥ 2% have been associated with atherosclerosis and chronic heart failure of ischemic origin (CHF). However, the effects of mutations in other driver genes for CH with low VAF (<2%) on CHF are still unknown.
Methods and results: Therefore, we analysed mononuclear bone marrow and blood cells from 399 CHF patients by deep error-corrected targeted sequencing of 56 genes and associated mutations with the long-term mortality in these patients (3.95 years median follow-up). We detected 1113 mutations with a VAF ≥ 0.5% in 347 of 399 patients, and only 13% had no detectable CH. Despite a high prevalence of mutations in the most frequently mutated genes DNMT3A (165 patients) and TET2 (107 patients), mutations in CBL, CEBPA, EZH2, GNB1, PHF6, SMC1A, and SRSF2 were associated with increased death compared with the average death rate of all patients. To avoid confounding effects, we excluded patients with DNMT3A-related, TET2-related, and other clonal haematopoiesis of indeterminate potential (CHIP)-related mutations with a VAF ≥ 2% for further analyses. Kaplan–Meier survival analyses revealed a significantly higher mortality in patients with mutations in either of the seven genes (53 patients), combined as the CH-risk gene set for CHF. Baseline patient characteristics showed no significant differences in any parameter including patient age, confounding diseases, severity of CHF, or blood cell parameters except for a reduced number of platelets in patients with mutations in the risk gene set in comparison with patients without. However, carrying a mutation in any of the risk genes remained significant after multivariate cox regression analysis (hazard ratio, 3.1; 95% confidence interval, 1.8–5.4; P < 0.001), whereas platelet numbers did not.
Conclusions: Somatic mutations with low VAF in a distinct set of genes, namely, in CBL, CEBPA, EZH2, GNB1, PHF6, SMC1A, and SRSF2, are significantly associated with mortality in CHF, independently of the most prevalent CHIP-mutations in DNMT3A and TET2. Mutations in these genes are prevalent in young CHF patients and comprise an independent risk factor for the outcome of CHF, potentially providing a novel tool for risk assessment in CHF.
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent lymphoma, but can transform into diffuse large B cell lymphoma (DLBCL), showing a more aggressive clinical behavior. Little is known about these cases on the molecular level. Therefore, the aim of the present study was to characterize DLBCL transformed from NLPHL (LP-DLBCL) by gene expression profiling (GEP). GEP revealed an inflammatory signature pinpointing to a specific host response. In a coculture model resembling this host response, DEV tumor cells showed an impaired growth behavior. Mechanisms involved in the reduced tumor cell proliferation included a downregulation of MYC and its target genes. Lack of MYC expression was also confirmed in 12/16 LP-DLBCL by immunohistochemistry. Furthermore, CD274/PD-L1 was upregulated in DEV tumor cells after coculture with T cells or monocytes and its expression was validated in 12/19 cases of LP-DLBCL. Thereby, our data provide new insights into the pathogenesis of LP-DLBCL and an explanation for the relatively low tumor cell content. Moreover, the findings suggest that treatment of these patients with immune checkpoint inhibitors may enhance an already ongoing host response in these patients.
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7 + 3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA).
Patients and methods: Patients with newly diagnosed AML >60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1–3) (IMA) or standard induction therapy with cytarabine (100 mg/m2 continuously days 1–7) plus daunorubicin (45 mg/m2 days 3–5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone.
Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33–45] versus 55% (95% CI: 49–61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513).
Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.
Background: Fumaric acid esters (FAEs; Fumaderm®) are the most frequently prescribed first-line systemic treatment for moderate-to-severe plaque psoriasis in Germany. Risankizumab (Skyrizi®) is a humanized IgG1 monoclonal antibody that specifically binds to the p19 subunit of interleukin 23. Objectives: To compare risankizumab treatment to FAEs in patients with psoriasis. Methods: This phase III randomized, active-controlled, open-label study with blinded assessment of efficacy was conducted in Germany. Patients were randomized (1 : 1) to subcutaneous risankizumab 150 mg (weeks 0, 4 and 16) or oral FAEs at increasing doses from 30 mg daily (week 0) up to 720 mg daily (weeks 8–24). Enrolled patients were adults naïve to and candidates for systemic therapy, with chronic moderate-to-severe plaque psoriasis. Phototherapy was not allowed within 14 days before or during the study. Results: Key efficacy endpoints were met at week 24 for risankizumab (n = 60) vs. FAEs (n = 60) (P < 0·001): achievement of a ≥ 90% improvement in Psoriasis Area and Severity Index (PASI; primary endpoint 83·3% vs. 10·0%), ≥ 100% improvement in PASI (50·0% vs. 5·0%), ≥ 75% improvement in PASI (98·3% vs. 33·3%), ≥ 50% improvement in PASI (100% vs. 53·3%) and a Static Physician’s Global Assessment of clear/almost clear (93·3% vs. 38·3%). The rates of gastrointestinal disorders, flushing, lymphopenia and headache were higher in the FAE group. One patient receiving risankizumab reported a serious infection (influenza, which required hospitalization). There were no malignancies, tuberculosis or opportunistic infections in either treatment arm. Conclusions: Risankizumab was found to be superior to FAEs, providing earlier and greater improvement in psoriasis outcomes that persisted with continued treatment, and more favourable safety results, which is consistent with the known safety profile. No new safety signals for risankizumab or FAEs were observed.
There is a need for diagnostic biomarkers of epilepsy and status epilepticus to support clinical examination, electroencephalography and neuroimaging. Extracellular microRNAs may be potentially ideal biomarkers since some are expressed uniquely within specific brain regions and cell types. Cerebrospinal fluid offers a source of microRNA biomarkers with the advantage of being in close contact with the target tissue and sites of pathology. Here we profiled microRNA levels in cerebrospinal fluid from patients with temporal lobe epilepsy or status epilepticus, and compared findings to matched controls. Differential expression of 20 microRNAs was detected between patient groups and controls. A validation phase included an expanded cohort and samples from patients with other neurological diseases. This identified lower levels of miR-19b in temporal lobe epilepsy compared to controls, status epilepticus and other neurological diseases. Levels of miR-451a were higher in status epilepticus compared to other groups whereas miR-21-5p differed in status epilepticus compared to temporal lobe epilepsy but not to other neurological diseases. Targets of these microRNAs include proteins regulating neuronal death, tissue remodelling, gliosis and inflammation. The present study indicates cerebrospinal fluid contains microRNAs that can support differential diagnosis of temporal lobe epilepsy and status epilepticus from other neurological and non-neurological diseases.
Effects of BPA in snails
(2006)
It is an ethical requirement that new findings be presented in light of and in conjunction with a balanced evaluation of the current knowledge and published literature. We believe that Oehlmann et al. (2006) violated this general principle in several ways. For example, the authors inferred that prosobranch snails have a functional estrogen receptor and therefore a much higher sensitivity to estrogens and endocrine-disrupting compounds (EDCs) than other species previously reported in the literature. We found several other problems in their article...
Background: The inclusion of immune checkpoint inhibitors (ICIs) in therapeutic algorithms has led to significant survival benefits in patients with various metastatic cancers. Concurrently, an increasing number of neurological immune related adverse events (IRAE) has been observed. In this retrospective analysis, we examine the ICI-induced incidence of cerebral pseudoprogression and propose a classification system.
Methods: We screened our hospital information system to identify patients with any in-house ICI treatment for any tumor disease during the years 2007-2019. All patients with cerebral MR imaging (cMRI) of sufficient diagnostic quality were included. cMRIs were retrospectively analyzed according to immunotherapy response assessment for neuro-oncology (iRANO) criteria.
Results: We identified 12 cases of cerebral pseudoprogression in 123 patients treated with ICIs and sufficient MRI. These patients were receiving ICI therapy for lung cancer (n=5), malignant melanoma (n=4), glioblastoma (n=1), hepatocellular carcinoma (n=1) or lymphoma (n=1) when cerebral pseudoprogression was detected. Median time from the start of ICI treatment to pseudoprogression was 5 months. All but one patient developed neurological symptoms. Three different patterns of cerebral pseudoprogression could be distinguished: new or increasing contrast-enhancing lesions, new or increasing T2 predominant lesions and cerebral vasculitis type pattern.
Conclusion: Cerebral pseudoprogression followed three distinct patterns and was detectable in 3.2% of all patients during ICI treatment and in 9.75% of the patients with sufficient brain imaging follow up. The fact that all but one of the affected patients developed neurological symptoms, which would be classified as progressive disease according to iRANO criteria, mandates vigilance in the diagnosis and treatment of ICI-induced cerebral lesions.
Background: Epileptic seizures are common clinical features in patients with acute subdural hematoma (aSDH); however, diagnostic feasibility and therapeutic monitoring remain limited. Surface electroencephalography (EEG) is the major diagnostic tool for the detection of seizures but it might be not sensitive enough to detect all subclinical or nonconvulsive seizures or status epilepticus. Therefore, we have planned a clinical trial to evaluate a novel treatment modality by perioperatively implanting subdural EEG electrodes to diagnose seizures; we will then treat the seizures under therapeutic monitoring and analyze the clinical benefit.
Methods: In a prospective nonrandomized trial, we aim to include 110 patients with aSDH. Only patients undergoing surgical removal of aSDH will be included; one arm will be treated according to the guidelines of the Brain Trauma Foundation, while the other arm will additionally receive a subdural grid electrode. The study's primary outcome is the comparison of incidence of seizures and time-to-seizure between the interventional and control arms. Invasive therapeutic monitoring will guide treatment with antiseizure drugs (ASDs). The secondary outcome will be the functional outcome for both groups as assessed via the Glasgow Outcome Scale and modified Rankin Scale both at discharge and during 6 months of follow-up. The tertiary outcome will be the evaluation of chronic epilepsy within 2-4 years of follow-up.
Discussion: The implantation of a subdural EEG grid electrode in patients with aSDH is expected to be effective in diagnosing seizures in a timely manner, facilitating treatment with ASDs and monitoring of treatment success. Moreover, the occurrence of epileptiform discharges prior to the manifestation of seizure patterns could be evaluated in order to identify high-risk patients who might benefit from prophylactic treatment with ASDs.
Trial registration: ClinicalTrials.gov identifier no. NCT04211233.
Background: In September 2018, Burkholderia cepacia complex (BCC) infections in 3 patients associated with exposure to a mouthwash solution (MWS) were reported to the Robert Koch Institute (RKI). As the product was still on the market and the scale of the outbreak was unclear, a nation-wide investigation was initiated.
Methods: We aimed to investigate BCC infections/colonizations associated with MWS. Hospitals, laboratories, and public health services were informed that BCC isolates should be sent to the RKI. These isolates were typed by pulsed-field gel electrophoresis (PFGE) and whole-genome sequencing (WGS) including development of an ad hoc core genome MLST (cgMLST) scheme.
Results: In total, 36 patients from 6 hospitals met the case definition, the last patient in November 2018. Twenty-nine isolates from 26 of these patients were available for typing. WGS analysis revealed 2 distinct cgMLST clusters. Cluster 1 (Burkholderia arboris) contained isolates from patients and MWS obtained from 4 hospitals and isolates provided by the manufacturer. Patient and MWS isolates from another hospital were assigned to cluster 2 (B. cepacia).
Conclusions: The combined clinical, epidemiological, and microbiological investigation, including whole-genome analysis, allowed for uncovering a supraregional BCC outbreak in health care settings. Strains of B. arboris and B. cepacia were identified as contaminating species of MWS bottles and subsequent colonization and putative infection of patients in several hospitals. Despite a recall of the product by the manufacturer in August 2018, the outbreak lasted until December 2018. Reporting of contaminated medical products and recalls should be optimized to protect patients.
The radiative electron capture (REC) into the K shell of bare Xe ions colliding with a hydrogen gas target has been investigated. In this study, the degree of linear polarization of the K-REC radiation was measured and compared with rigorous relativistic calculations as well as with the previous results recorded for U92+. Owing to the improved detector technology, a significant gain in precision of the present polarization measurement is achieved compared to the previously published results. The obtained data confirms that for medium-Z ions such as Xe, the REC process is a source of highly polarized x rays which can easily be tuned with respect to the degree of linear polarization and the photon energy. We argue, in particular, that for relatively low energies the photons emitted under large angles are almost fully linear polarized.